The negative correlation between BPH-size and incidence of prostate cancer (PCa) is well-documented in the literature, however the exact mechanism is not well-understood. The present study uses histo-anatomical imaging to study prostate volume in correlation to prostate capsule thickness, and glandular epithelial cell density within the peripheral zone (PZ).
(UroToday.com) Advances in imaging have dramatically reshaped prostate cancer diagnosis, staging, and treatment. In terms of diagnosis, multiparametric MRI (mpMRI) of the prostate has been increasingly utilized for risk stratification in men with elevated prostate specific antigen (PSA) levels and to guide biopsy. On the basis of randomized controlled trials mpMRI followed by targeted biopsy […]
(UroToday.com) Radiotherapy and radical prostatectomy are common and guideline-recommended treatment for patients with localized prostate cancer. With each treatment approach, the risk of disease recurrence is non-negligible. For men who are initially treated with radiotherapy, most recurrences are managed with systemic androgen deprivation therapy with the associated systemic toxicity and subsequent development of castration resistance. […]
(UroToday.com) Following three presentations regarding both radiologic and genomic approaches for prostate cancer diagnosis and risk stratification in the Prostate, Testicular, Penile Poster Discussion session at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Taneja provided a discussant overview of these data and helped to contextualize how we may apply them to […]
(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) in the last 10 years. While the most commonly utilized approaches in prostate cancer are cytotoxic chemotherapy or target the androgen-axis (including abiraterone acetate and enzalutamide), subtypes of prostate cancer, including neuroendocrine prostate cancer, have a particularly […]
(UroToday.com) Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) need therapy that prolongs survival with little added toxicity, thus preserving quality of life. The second-generation androgen receptor inhibitors including darolutamide, apalutamide, and enzalutamide offer durable survival in nmCRPC but differences exist in adverse event profiles (ie. fatigue, falls, fractures, rash, mental impairment, and hypertension) that can limit […]
(UroToday.com) One of the fastest moving disease spaces in prostate cancer in metastatic castration sensitive prostate cancer (mCSPC). While androgen-deprivation therapy (ADT) alone was the standard treatment five years ago, now there are a number of treatment options that have been shown to improve overall survival, including docetaxel and novel hormonal therapies including abiraterone acetate, enzalutamide, […]
(UroToday.com) For patients diagnosed with very high-risk prostate cancer who opt for radiotherapy, the guideline-recommended standard of care is concomitant treatment with 18 to 36 months of androgen-deprivation therapy (ADT). While associated with better cancer control than radiotherapy alone or radiotherapy in combination with short-durations of ADT, this regime is still associated with not infrequent […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University in Chicago. I’m so excited to have here with me today, a good friend and colleague, Dr. Petros Grivas, who is an Associate Professor and the Clinical Director of the GU Cancers Program […]
Alicia Morgans: Hi, my name is Alicia Morgans, and I am a GU Medical Oncologist, and an Associate Professor of Medicine at Northwestern University in Chicago. I am so excited to have here with me today, a good friend and colleague, Dr. Scott Tagawa, who is a Professor of Medicine at Weill Cornell at New […]
